- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chitra Lal: Low Threshold Screening Needed for OSA
Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, says that the screening threshold for obstructive sleep apnea (OSA) should be low because 70% to 75% of patients with mild cognitive impairment have sleep apnea.
Screening for obstructive sleep apnea (OSA) early and treating it aggressively may help reduce the risk of mild cognitive impairment, says Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, in this interview from the 2023 American Thoracic Society (ATS) International Conference.
Transcript
What are some of the challenges associated with treating patients with OSA and Alzheimer disease and what do you think more providers should know about this population?
I think it's important to recognize that sleep apnea is a modifiable risk factor for mild cognitive impairment and Alzheimer disease, and therefore recognizing it early and treating it aggressively would be the key. Providers should have a low threshold for screening for sleep apnea in this patient population because there are studies which have shown that at least 70% to 75% of patients with mild cognitive impairment are proven to have sleep apnea. So, I think diagnosing it early and treating it aggressively is extremely important.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
